Why This Top-Notch IPO Stock Just Broke Out In Bullish Volume

Recent initial public offering Arcellx (ACLX) forged a $325 million multiple myeloma deal with Gilead Sciences (GILD) on Friday, and the IPO stock broke out.X The news comes in lockstep with promising long-term results for Arcellx's multiple myeloma treatment. Every patient with at least one month…#usarcellx #gileadsciences #kitepharma #ipostock #aclx #crs #gilead #myelomadrug #marketsmithcom #arcellx

Source: Reuters: Health - December 9, 2022 Category: Consumer Health News Source Type: news